ONECUT2 Drives Neuroendocrine Prostate Cancer Through Hypoxia Signaling

Haiyang Guo1, Musaddeque Ahmed1, Junjie Tony Hua1,2, Fraser Soares1, Dong Lin3,4, Estelle Li3, Peiran Su1,2, Tran Nguyen1, Yi Liang1, Yuzhe Zhang1,5,6, Xin Xu1, Jing Xu1, Wail Ba-Alawi1, Si Zhang1, Osman Mahamud1,2, Ravi N. Vellanki1, Marianne Koritzinsky1,7, Martin Gleave3, Robert G. Bristow1,2, Benjamin Haibe-Kains1,2,8,9, Ming-Sound Tsao1,10, Bradly G. Wouters1,2,7, Felix Y. Feng11-14, Ladan Fazli3, Paul C. Boutros2,9,15, Amina Zoubeidi3, Yuzhuo Wang1,4, Housheng Hansen He1,2,16,*

1 Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; 2 Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; 3 The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia, Vancouver, British Columbia, Canada; 4 Department of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, British Columbia, Canada; 5 College of Life Sciences, Central China Normal University, Wuhan, Hubei, P.R China; 6 College of Basic Medical Sciences, Dali University, Dali, Yunnan, P.R China; 7 Department of Radiation Oncology and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8 Department of Computer Science, University of Toronto, Toronto, ON, Canada; 9 Ontario Institute for Cancer Research, Toronto, Ontario, Canada; 10 Department of Pathology, University of Toronto, Toronto, ON, Canada; 11 Department of Radiation Oncology, University of California at San Francisco, San Francisco, CA, USA; 12 Department of Urology, University of California at San Francisco, San Francisco, CA, USA; 13 Department of Medicine, University of California at San Francisco, San Francisco, CA, USA; 14 Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA; 15 Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; 16 Lead Contact.

*Correspondence: hansenhe@uhnresearch.ca

ABSTRACT

Background: Neuroendocrine prostate cancer (NEPC), a lethal form of the disease, is characterized by the loss of androgen receptor (AR) pathway and subsequently AR expression during neuroendocrine transdifferentiation, which results in resistance to AR-targeted therapy. Histologically and clinically, NEPC resembles other types of small cell neuroendocrine tumors such as small cell lung cancer.

Methods: Through a pan-neuroendocrine cancer analysis, we identified ONECUT2 (OC2) as a candidate master transcriptional regulator of neuroendocrine tumors including prostate cancer.

Results: ONECUT2 alone was sufficient to induce neuroendocrine transdifferentiation in prostate adenocarcinoma and synergized with hypoxia in driving NEPC. Specifically, ONECUT2 regulates hypoxia signaling through modulation of HIF1A chromatin-binding, leading to NEPC being more hypoxic than prostate adenocarcinomas. Treatment with hypoxia-activated prodrug TH-302 potently reduces tumor growth in NEPC patient-derived xenograft models.

Conclusions: Collectively, these results suggest that ONECUT2 drives NEPC through hypoxia signaling, and emphasize the potential of hypoxia-directed therapy for patients with NEPC.

CONFLICT of INTEREST: The authors declare no conflicts of interest.

FUNDING ACKNOWLEDGMENTS

The work was supported by Princess Margaret Cancer Foundation (to H.H.H), Canada Foundation for Innovation and Ontario Research Fund (CFI32372 to H.H.H), NSERC discovery grant (498706 to H.H.H), WICC Ontario 20th Anniversary Prostate Cancer Innovation Grant of the CCS (703800 to H.H.H), CIHR operating grant (142246 to H.H.H), Movember Rising Star awards from Prostate Cancer Canada (RS2014-01 to P.C.B and RS2016-1022 to H.H.H). H.H.H. holds an ICS-IG Maud Menten New Principal Investigator Prize (ICS-145381) and an OMIR Early Researcher Award. J.H
is a CIHR Graduate Student Fellowship recipient. The results shown here are in whole or part based upon data generated by the TCGA Research Network.